Cbl0137

Manufactured by Selleck Chemicals

CBL0137 is a lab equipment product. It is a compact benchtop device designed for general laboratory use. The core function of CBL0137 is to provide a controlled environment for various experimental procedures.

Automatically generated - may contain errors

Lab products found in correlation

Rucaparib, by Selleck Chemicals (1 mentions) Olaparib, by Selleck Chemicals (1 mentions) Athymic nude mice, by Charles River Laboratories (1 mentions) Tunel assay, by Abcam (1 mentions) Caspase 3, by Santa Cruz Biotechnology (1 mentions) Hydroxypropyl β cyclodextrin, by Merck Group (1 mentions) Dinaciclib, by Selleck Chemicals (1 mentions)

4 protocols using cbl0137

Preparation and Use of CBL0137 Compound

Check if the same lab product or an alternative is used in the 5 most similar protocols

CBL0137 was obtained from Selleck Chemicals (#S8483) and was diluted in DMSO for storage of stock solutions. Working concentrations were made immediately before use and diluted in cell media or sterile saline (Pharmaceutical Grade 0.9% Sodium Chloride, Henry Schein, Pfizer Injectables) for in vitro and in vivo studies, respectively. Sterile saline served as the vehicle control for in vivo studies and DMSO at a final percentage equivalent to that of the drug suspensions served as the vehicle control for all in vitro studies.

Tallman M.M., Zalenski A.A., Deighen A.M., Schrock M.S., Mortach S., Grubb T.M., Kastury P.S., Huntoon K., Summers M.K, & Venere M. (2020). The small molecule drug CBL0137 increases the level of DNA damage and the efficacy of radiotherapy for glioblastoma. Cancer letters, 499, 232-242.

+ Open protocol

+ Expand

Characterization of Ovarian Cancer Cell Lines

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

HGSC cell lines including OVCAR-8, OVCAR-4, OVCAR-3, Kuramochi, CAOV3, OV90, and OAW42 and non-cancerous ovarian epithelial cell lines HOSE6.3 and HOSE17.1 were kindly provided by Dr. Elaine Sanij (St Vincent’s Hospital, QLD). PEO1 and PEO4 cell lines were provided by Prof John Hooper. BRCA1/2 gene mutation status and HR status of HGSC established cell lines is given in Additional file 3 Table S1. All HGSC cell lines were cultured in RPMI1640 media containing 10% fetal bovine serum (FBS) (Gibco). Murine ID8 (both ID8 p53^−/− and ID8 p53^−/− BRCA1^−/−) cells [29 (link)] were kindly provided by Prof Iain McNeish at Imperial College of London. All cell lines were tested for Mycoplasma infection at QIMR Berghofer Medical Research Institute. CBL0137 (Cat #: S8483), Olaparib (Cat #: S1060) and Rucaparib (Cat #: S4948) were purchased from Selleck Chemicals.

Lu X., He Y., Johnston R.L., Nanayakarra D., Sankarasubramanian S., Lopez J.A., Friedlander M., Kalimutho M., Hooper J.D., Raninga P.V, & Khanna K.K. (2022). CBL0137 impairs homologous recombination repair and sensitizes high-grade serous ovarian carcinoma to PARP inhibitors. Journal of Experimental & Clinical Cancer Research : CR, 41, 355.

+ Open protocol

+ Expand

Combinatorial Therapy for Medulloblastoma

Check if the same lab product or an alternative is used in the 5 most similar protocols

All animal experiments were performed with the approval of the UNMC Institutional Animal Care and Use Committee (IACUC). HD-MB03 and ONS-76 cells (1×10⁶ in 100 μl medium with matrigel) were injected subcutaneously over the left and right flanks in athymic nude mice (Charles Rivers, Wilmington, MA). Subcutaneous tumors were allowed to grow for 2–3 weeks before treatments. The mice were divided into four treatment groups (n=5 mice per group) and received treatments every other day for four weeks. The following drugs: cisplatin (2 mg/kg), CBL0137 (30 mg/kg; Selleck Chemicals, LLC.) were injected intraperitoneally. The combination group received both cisplatin and CBL0137. DMSO was given to the control group. Body weight and tumor volume were measured before each treatment. The mice were euthanized at the end of treatment cycles. Antibodies used for Xenograft tumor IHC included AcAPE1, Ki67 (1:500, CST, 9027), SSRP1, Caspase 3 (1:100, Santa Cruz, sc-7272) and TUNEL assay (Abcam, ab206386). Additive or synergistic effect was examined using the online tool SynergyFinder (https://svnergyfinder.fimm.fi).

Song H., Xi S., Chen Y., Pramanik S., Zeng J., Roychoudhury S., Harris H., Akbar A., Elhag S.S., Coulter D.W., Ray S, & Bhakat K.K. (2021). Histone chaperone FACT Complex inhibitor CBL0137 interferes with DNA damage repair and enhances sensitivity of Medulloblastoma to chemotherapy and radiation. Cancer letters, 520, 201-212.

+ Open protocol

+ Expand

Genetic Modulation of Lung Tumor Growth

Check if the same lab product or an alternative is used in the 5 most similar protocols

Kras^LSL–G12D/+ transgenic mice were obtained from the Jackson Laboratory. The Setd2^fl/fl mice were generated by Beijing Biocytogen Co. Ltd. Kras^LSL–G12D/+ and Setd2^fl/fl mice were bred to generate Kras^LSL–G12D/+ Setd2^fl/+ and Kras^LSL–G12D/+ Setd2^fl/fl mice. All animals were maintained on a mixed C57BL/6J × 129SvJ genetic background. Intranasal instillation of 2.5 × 10⁷ plaque-forming units (pfu) of adenovirus-expressing Cre (Viral Vector Core Facility, University of Iowa, Iowa City, Iowa, USA) was performed on mice at 6–10 weeks of age as previously described (49 (link)). Tumor growth was monitored by MRI scans. Sex-matched Kras^LSL–G12D/+ Setd2^fl/fl mice, 4 weeks after adeno-Cre infection, were randomized into vehicle control and Dinaciclib or CBL0137 treatment groups. CBL0137 (Selleck Chemicals) was formulated in 50 mg/mL Captisol and administered i.v. twice weekly at 60 mg/kg for 4 weeks. Dinaciclib (Selleck Chemicals) was formulated in 20% hydroxypropyl β-cyclodextrin (MilliporeSigma) and administered i.p. 3 times weekly at 20 mg/kg. Lung tumor growth was assessed by MRI scans at 7 weeks after the first treatment. The body weights of the mice were monitored twice weekly.

Xie Y., Sahin M., Wakamatsu T., Inoue-Yamauchi A., Zhao W., Han S., Nargund A.M., Yang S., Lyu Y., Hsieh J.J., Leslie C.S, & Cheng E.H. (2023). SETD2 regulates chromatin accessibility and transcription to suppress lung tumorigenesis. JCI Insight, 8(4), e154120.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!